Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253099 | 0.83 | CA1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL27818014 | 0.78 | ADRA2A (0.33) | L3MBTL1NQO2MAPTALDH1A1HPGD | |
| SCHEMBL171713 | 0.77 | — | — | |
| SCHEMBL25874735 | 0.76 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4136425 | 0.76 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30772335 | 0.76 | CA12 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16590519 | 0.76 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL78713 | 0.76 | CA12 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29635862 | 0.75 | — | — | |
| SCHEMBL12541 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683621-B | Organic compound, electronic element comprising same and electronic device | 陕西莱特迈思光电材料有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023016528-A1 | CLASS OF BENZOMORPHOLINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京明德新药研发有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| CN-113683621-A | Organic compound, electronic element containing organic compound and electronic device | 陕西莱特迈思光电材料有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | disclosed |
| WO-2012027579-A1 | SYNTHETIC TRITERPENOID DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| CN-100439330-C | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | LUNDBECK & CO AS H (DK) | 2008-12-03 | — | — | CN | disclosed |
| EP-1607401-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | Metabasis Therapeutics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2004096761-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | CA1 2648/4885CA2 974/4885CA7 1841/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | CA1 2648/4885CA2 974/4885CA7 1841/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | CA1 4016/4885CA2 2484/4885CA7 2806/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | CA1 4224/4885CA2 2458/4885CA7 2873/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | CA1 4602/4885CA2 2237/4885CA7 2479/4885 |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | CA1 4602/4885CA2 2237/4885CA7 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.